Zhongchao (NASDAQ:ZCMD – Get Free Report) was downgraded by equities researchers at Wall Street Zen from a “sell” rating to a “strong sell” rating in a report released on Saturday, Wall Street Zen reports.
Separately, Weiss Ratings downgraded shares of Zhongchao from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, September 25th. One investment analyst has rated the stock with a Sell rating. According to MarketBeat.com, Zhongchao currently has an average rating of “Sell”.
View Our Latest Stock Analysis on Zhongchao
Zhongchao Stock Performance
Zhongchao Company Profile
Zhongchao Inc (NASDAQ: ZCMD) is a China-based healthcare services company focused on medical education and patient management. Through its operating subsidiaries, the company provides services intended to support healthcare professionals, patients and pharmaceutical or medical-product companies, with an emphasis on oncology and other chronic disease areas.
Zhongchao’s medical education activities have included online and offline educational programs, academic conferences, seminars and other professional training initiatives for physicians and healthcare providers.
See Also
- Five stocks we like better than Zhongchao
- Marvell Eyes a Swing for the AI Networking Fences as Markets Weigh Lumentum Price Tag
- Exxon’s Refining Profits Soared—Did Chevron Get the Same Windfall?
- Eli Lilly’s First Full Medicare Quarter: Is Volume Still Outrunning Price Cuts?
- Oracle’s AI Spending Peak Is in Sight—Can the Stock Recover?
Receive News & Ratings for Zhongchao Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zhongchao and related companies with MarketBeat.com's FREE daily email newsletter.
